Higher proportion of participants achieved HbA1c levels below 6.5% with canagliflozin VS placebo. HealthDay News — Canagliflozin is associated with a clinically meaningful reduction in hemoglobin A1c ...

A Phase III, international, randomized clinical trial assessed the safety and efficacy of canagliflozin for the treatment of type 2 diabetes mellitus (T2DM) in children and adolescents. The study ...

Cardiovascular benefits associated with the SGLT2 inhibitor drug canagliflozin appear to be dose-dependent, with benefits in some key clinical endpoints — including mortality — observed only in the ...

Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on ...

Please provide your email address to receive an email when new articles are posted on . Canagliflozin was associated with a 2.1% increase in total iron-binding capacity. Hemoglobin increased by 7.3 ...

Aging-related physiological decline and the accumulation of senescent or aging cells in bodily tissues can trigger a number of diseases. The removal of senescent cell, also known as ‘senolysis,’ can ...

CAPITAL CITY. THERE’S MORE THAN TWO CENTURIES OF HISTORY IN THE GRANITE STATE’S CAPITAL CITY, BUT ITS VERY NAME HAS AN INTERESTING POWER. PRONOUNCE IT WRONG AND YOU’LL BE TELLING EVERYONE ONE THING ...

This article is part of The Salt Lake Tribune’s New to Utah series. For more articles on Utah’s food, culture, history, outdoors and more, sign up for the ...

Sooner or later the moment will arrive for everyone, or at least everyone who doesn’t speak Arabic but hopes to discuss this year’s World Cup without sounding like a total idiot. What happens when ...

Please provide your email address to receive an email when new articles are posted on . The SGLT2 inhibitor canagliflozin improved HF symptoms within 3 months in patients with HF, regardless of ...

In the CREDENCE trial, patients receiving canagliflozin had reduced risks of initiating iron therapy and erythropoiesis-stimulating agents compared with patients receiving placebo. In addition to its ...